| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 1.0K | 6.3% | 9.7% |
| Total Income | 1.1K | 5.9% | 9.0% |
| Expenditure | 691.43 | 4.4% | 2.2% |
| PBT | 399.93 | 13.0% | 29.8% |
| Net Profit | 295.62 | 14.8% | 28.6% |
| OPM | 37.39% | 2.86pp | 10.62pp |
| NPM | 27.54% | 2.13pp | 4.19pp |
| EPS | 16.54 | 9.8% | 21.9% |
GSK India Crosses INR 1000 cr In Topline, Key Portfolios Deliver 8.1% Growth in Q3 2025
09 Feb 2026 · 9 Feb, 3:53 pm
Summary
GlaxoSmithKline Pharmaceuticals Ltd (GSK India) announced its financial results for the third quarter ended December 31, 2025. The company witnessed growth across its key portfolios, leading to overall topline expansion and well-managed profitability through cost discipline. The General Medicines portfolio performed well, with the top five promoted brands growing ahead of the market. The Vaccines business saw market share expansion, and the Oncology business is gaining traction. The company is expanding engagement with the Oncology fraternity and making steady progress in reaching patients with endometrial and recurrent ovarian cancer.
Key Highlights
- 1
Revenue from Operations was INR 1023 Crores
- 2
Profit After Tax (PAT) was INR 277 Crores
- 3
EBIDTA margins grew by 520bps to 35.9%
- 4
General Medicines portfolio delivered competitive performance
- 5
Vaccines business saw market share expansion
- 6
Oncology business is gaining traction
- 7
Implementation of the New Labour Codes 2025 did not have a material impact on the Company
Management Comments
Bhushan Akshikar
Managing Director, GSK India
By moving immunotherapy from later lines to initial standard of care, the RUBY-1 trial has established a new paradigm in first-line treatment of endometrial cancer, and is now approved for this indication in India. The positive results on progression-free survival and overall survival in the population under trial will simplify decision-making for HCPs on treatment lines and benefit a wide range of endometrial cancer patients. Supported by comprehensive patient support and financing initiatives, the Company is leaving no stone unturned to ensure patients with cancer receive the highest standard of care.
Informational and educational content only. Not investment advice.